Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer Prev Res (Phila) 2009 Dec;2(12):1059-64
Date
11/26/2009Pubmed ID
19934342Pubmed Central ID
PMC6001362DOI
10.1158/1940-6207.CAPR-09-0221Scopus ID
2-s2.0-76549125769 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.
Author List
Wang Y, Wen W, Yi Y, Zhang Z, Lubet RA, You MMESH terms used to index this publication - Major topics in bold
AdenoviridaeAnimals
Anti-Inflammatory Agents
Anticarcinogenic Agents
Apoptosis
Budesonide
Cell Proliferation
Disease Models, Animal
Female
Genetic Engineering
Immunoenzyme Techniques
In Situ Nick-End Labeling
Integrases
Lung Neoplasms
Male
Mice
Mice, Inbred A
Retinoblastoma Protein
Small Cell Lung Carcinoma
Tetrahydronaphthalenes
Tumor Suppressor Protein p53
